Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 9, 2011, Pages 1095-1103

  Kresken, M ^a   Becker, K ^b   Seifert, H ^c   Leitner, E ^d   Korber Irrgang B ^a   Von Eiff, C ^b,d   Loschmann P A ^d  

^a BONN RHEIN SIEG UNIVERSITY OF APPLIED SCIENCES   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; DOXYCYCLINE; ERTAPENEM; GENTAMICIN; IMIPENEM; LINEZOLID; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GERMANY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; INFANT; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SERRATIA MARCESCENS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GERMANY; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; YOUNG ADULT;

EID: 80054747514     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1197-y     Document Type: Article

References (36)

1. Fauci AS (2001) Infectious diseases: Considerations for the 21st century. Clin Infect Dis 32:675-685 (Pubitemid 32221924)
2. Armstrong GL, Conn LA, Pinner RW (1999) Trends in infectious disease mortality in the United States during the 20th century. JAMA 281:61-66 (Pubitemid 29025101)
3. Cohen ML (2000) Changing patterns of infectious disease. Nature 406:762-767
4. Bundesministerium für Gesundheit, Bundesministerium für Ernährung, Landwirtschaft und Verbraucherschutz, und Bundesministerium für Bildung und Forschung (2008) DART-Deutsche Antibiotika- Resistenzstrategie
5. Rice LB (2007) Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. Cleve Clin J Med 74(Suppl 4):S12-S20
6. Gootz TD (2010) The global problem of antibiotic resistance. Crit Rev Immunol 30:79-93
7. Fraise AP (2006) Tigecycline: The answer to beta-lactam and fluoroquinolone resistance? J Infect 53:293-300 (Pubitemid 44529222)
8. Rodríguez de Castro F, Naranjo OR, Marco JA, Violán JS (2009) New antimicrobial molecules and new antibiotic strategies. Semin Respir Crit Care Med 30:161-171
9. Peterson LR (2008) Currently available antimicrobial agents and their potential for use as monotherapy. Clin Microbiol Infect 14 (Suppl 6):30-45 (Pubitemid 352749379)
10. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME (2008) Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: A systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62:895-904
11. European Antimicrobial Resistance Surveillance System (EARSS) (2009) EARSS Annual Report 2008
12. Fritsche TR, Kirby JT, Jones RN (2004) In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 49:201-209 (Pubitemid 38891728)
13. Fluit AC, Florijn A, Verhoef J, Milatovic D (2005) Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 49:1636-1638 (Pubitemid 40463409)
14. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA (2003) Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 47:972-978 (Pubitemid 36254223)
15. Visalli MA, Murphy E, Projan SJ, Bradford PA (2003) AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 47:665-669 (Pubitemid 36158098)
16. Keeney D, Ruzin A, McAleese F, Murphy E, Bradford PA (2008) MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 61:46-53
17. McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, Bradford PA (2005) A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 49:1865-1871 (Pubitemid 40631601)
18. Ruzin A, Visalli MA, Keeney D, Bradford PA (2005) Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 49:1017-1022 (Pubitemid 40327718)
19. Kresken M, Leitner E, Brauers J, Geiss HK, Halle E, von Eiff C, Peters G, Seifert H (2009) Susceptibility of common aerobic pathogens to tigecycline: Results of a surveillance study in Germany. Eur J Clin Microbiol Infect Dis 28:83-90
20. Kresken M, Leitner E, Seifert H, Peters G, von Eiff C (2009) Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: Results of the second multicentre surveillance trial in Germany (G-TEST II, 2007). Eur J Clin Microbiol Infect Dis 28:1007-1011
21. Deutsches Institut für Normung (DIN) (2006) Labormedizinische Untersuchungen und In-vitro-Diagnostika-Systeme-Empfindlichkeitsprüfung von Infektionserregern und Evaluation von Geräten zur antimikrobiellen Empfindlichkeitsprüfung, Teil 1: Referenzmethode zur Testung der In-vitro-Aktivität von antimikrobiellen Substanzen gegen schnell wachsende aerobe Bakterien, die Infektionskrankheiten verursachen (ISO 20776-1:2006). Beuth-Verlag, Berlin
22. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2010) Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1 April 2010
23. Clinical and Laboratory Standards Institute (CLSI) (2009) Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement. CLSI document M100-S19. CLSI, Wayne, PA
24. Clinical and Laboratory Standards Institute (CLSI) (2008) Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement (M100-S18). CLSI, Wayne, PA
25. Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ (2010) In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints. Diagn Microbiol Infect Dis 66:187-19426.
26. Bantar C, Curcio D, Fernandez Canigia L, García P, Guzmán Blanco M, Leal AL (2009) Comparative in vitro activity of tigecycline against bacteria recovered from clinical specimens in Latin America. J Chemother 21:144-152
27. Wang YF, Dowzicky MJ (2010) In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008. Diagn Microbiol Infect Dis 68:73-79
28. Jones RN, Fritsche TR, Sader HS, Ross JE (2007) LEADER surveillance program results for 2006: An activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 59:309-317 (Pubitemid 350016703)
29. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B (2006) The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 50:2500-2505 (Pubitemid 43993192)
30. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, Andrade R, de la Torre MA, Fereres J, Sánchez-García M (2010) Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 50:821-825
31. Bonilla H, Huband MD, Seidel J, Schmidt H, Lescoe M, McCurdy SP, Lemmon MM, Brennan LA, Tait-Kamradt A, Puzniak L, Quinn JP (2010) Multicity outbreak of linezolidresistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. Clin Infect Dis 51:796-800
32. Lautenbach E, Fishman NO, Metlay JP, Mao X, Bilker WB, Tolomeo P, Nachamkin I (2006) Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: Results from a large hospitalbased surveillance initiative. J Infect Dis 194:79-85
33. Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, Donnelly AJ, Eckel SF, Eng RH, Hiltz A, Kuyumjian AG, Krebs W, McDaniel A, Hogan P, Lubowski TJ (2003) Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 37:1643-1648 (Pubitemid 37549951)
34. Boyd LB, Atmar RL, Randall GL, Hamill RJ, Steffen D, Zechiedrich L (2008) Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis 8:4
35. Protonotariou E, Dimitroulia E, Pournaras S, Pitiriga V, Sofianou D, Tsakris A (2010) Trends in antimicrobial resistance of clinical isolates of Enterococcus faecalis and Enterococcus faecium in Greece between 2002 and 2007. J Hosp Infect 75:225-227
36. Claesson C, Hällgren A, Nilsson M, Svensson E, Hanberger H, Nilsson LE (2007) Susceptibility of staphylococci and enterococci to antimicrobial agents at different ward levels in four north European countries. Scand J Infect Dis 39:1002-1012 (Pubitemid 350153872)